Tristetraprolin and Its Role in Regulation of Airway Inflammation by Pavan Prabhala & Alaina J Ammit
1521-0111/87/4/629–638$25.00 http://dx.doi.org/10.1124/mol.114.095984
MOLECULAR PHARMACOLOGY Mol Pharmacol 87:629–638, April 2015
Copyright ª 2015 by The American Society for Pharmacology and Experimental Therapeutics
MINIREVIEW
Tristetraprolin and Its Role in Regulation of Airway Inflammation
Pavan Prabhala and Alaina J. Ammit
Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
Received September 17, 2014; accepted November 26, 2014
ABSTRACT
Chronic inflammatory diseases, such as asthma and chronic
obstructive pulmonary disease (COPD), are clinically and
socioeconomically important diseases globally. Currently the
mainstay of anti-inflammatory therapy in respiratory diseases is
corticosteroids. Although corticosteroids have proven clinical
efficacy in asthma, many asthmatic inflammatory conditions
(e.g., infection, exacerbation, and severe asthma) are not respon-
sive to corticosteroids. Moreover, despite an understanding that
COPD progression is driven by inflammation, we currently do not
have effective anti-inflammatory strategies to combat this disease.
Hence, alternative anti-inflammatory strategies are required. p38
mitogen-activated protein kinase (MAPK) has emerged as an im-
portant signaling molecule driving airway inflammation, and phar-
macological inhibitors against p38 MAPK may provide potential
therapies for chronic respiratory disease. In this review, we dis-
cuss some of the recent in vitro and in vivo studies targeting p38
MAPK, but suggest that p38 MAPK inhibitors may prove less
effective than originally considered because they may block anti-
inflammatory molecules along with proinflammatory responses.
We propose that an alternative strategy may be to target an anti-
inflammatory molecule farther downstream of p38 MAPK,
i.e., tristetraprolin (TTP). TTP is an mRNA-destabilizing, RNA-
binding protein that enhances the decay of mRNAs, including
those encoding proteins implicated in chronic respiratory dis-
eases. We suggest that understanding the molecular mechanism
of TTP expression and its temporal regulation will guide future
development of novel anti-inflammatory pharmacotherapeutic
approaches to combat respiratory disease.
Introduction
Many chronic inflammatory diseases are a consequence of
overactive inflammatory signaling pathways. Hence, repressing
these pathways as potential drug targets represents a way
in which to re-establish control and attenuate the severity of
various chronic inflammatory diseases. However, these path-
ways are not exclusively responsible for proinflammatory
signaling, and targeting these pathwaysmay cause the ablation
of other vital, anti-inflammatory signals necessary for restoring
normal physiology. We propose that this may be the case with
targeting one of the members of the mitogen-activated protein
kinase (MAPK) superfamily, p38MAPK, in respiratory disease.
That is, while p38 MAPK inhibitors may repress proinflamma-
tory cytokines, they may also inhibit the expression of crucial
anti-inflammatory proteins, such as tristetraprolin (TTP). TTP
is an mRNA-destabilizing, RNA-binding protein that promotes
the decay of the mRNAs of many proteins, including those
implicated as playing a role in chronic respiratory diseases. In
this review, we focus on the role of the p38 MAPK signaling
pathway in respiratory disease and highlight some in vitro and
in vivo evidence with p38 MAPK inhibitors. We outline the role
of TTP in the regulation of inflammation in other disease
settings and highlight the potential of understanding the
molecular mechanism of TTP expression and its temporal
regulation for future development of novel anti-inflammatory
pharmacotherapeutic approaches in respiratory disease.
MAPK
Members of the MAPK superfamily play important roles in
the regulation of airway inflammation in respiratory disease
pathogenesis. Threewell defined phosphoproteins, extracellular
signal–related kinase (ERK), c-Jun N-terminal kinase, and p38
MAPK, are the MAPKs central to this signaling cascade. The
signaling cascade that results in the activation of MAPKs is
derived from a relatively linear framework (Fig. 1). Stimuli such
as cellular stressors or mitogens interact in a predominantly
receptor-mediated manner to trigger the phosphorylation of
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oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide; PKC, protein kinase C; SB202190, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole;
SB203580, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)imidazole; SB239063, trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-
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a specific MAPK kinase kinase, which then causes the phos-
phorylation of its specific downstream MAPK kinase. Once the
MAPK kinase is phosphorylated, it is subsequently able to
phosphorylate its own substrateMAPK. ActivatedMAPKs then
represent a point of divergence leading to the phosphorylation of
numerous downstream transcription factors, protein kinases,
and proto-oncogenes (Ashwell, 2006; Hu et al., 2007; Balaka-
thiresan et al., 2009). In this review, we focus on p38MAPK and
its downstream signaling effectors. The p38 MAPK–mediated
pathway regulates a plethora of cellular processes that drive
chronic airway inflammatory disease (Chung, 2011). Extensive
investigation of the p38 MAPK–driven molecular mechanisms
responsible for respiratory disease pathogenesis has led to drug
discovery programs that target this pathway as an approach to
potential anti-inflammatory therapy. Moreover, p38MAPK has
also been significantly implicated in corticosteroid insensitivity
(Ammit, 2013).
p38 MAPK: Role in Airway Inflammation and
Corticosteroid Insensitivity
There are four isoforms of p38 MAPK—a, b, d, and g—
transcribed by four separate genes and characterized by
different expression patterns. p38a is expressed ubiquitously
and, along with p38b, is considered to represent the major
isoform responsible for inflammatory responses. Inflamma-
tion is a central component of many respiratory diseases,
especially asthma and chronic obstructive pulmonary disease
(COPD), and the use of selective pharmacological inhibitors
has positioned p38 MAPK as playing a major role in disease
severity and progression. The majority of the in vitro studies
have used the inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-
methylsulfinylphenyl)-5-(4-pyridyl)imidazole], a pyridinyl im-
idazole that binds competitively at the ATP-binding site of
p38 MAPK. It is widely considered to predominantly target
p38a and p38b, but not the d and g isoforms of p38 MAPK,
although questions regarding selectively have been raised,
especially at higher doses (Bain et al., 2007). Nevertheless,
extensive investigations utilizing this first-generation in-
hibitor have yielded much valuable information regarding
the role of p38 MAPK in chronic respiratory disease. p38
MAPK regulates the immunomodulatory function of various
airway cells through the control of chemokine and cytokine
release (Amrani et al., 2001; Hallsworth et al., 2001; Henness
et al., 2006; Quante et al., 2008). p38 MAPK is also responsible
for neutrophil and eosinophil migration (Rousseau et al., 1997);
Fig. 1. Current and potential inhibitory targets to control p38 MAPK–dependent signaling in respiratory disease. The three members of the MAPK
superfamily—ERK, c-Jun N-terminal kinase (JNK), and p38 MAPK (p38)—are stimulated via a series of steps involving MAPK kinase kinases
(MAPKKKs) phosphorylating downstream MAPK kinases (MAPKKs), then ultimately MAPKs. This figure focuses on downstream effectors of the p38
MAPK pathway, and the numbers indicate inhibitory strategies along this pathway. While (1) and (2) will repress p38 MAPK, we propose that blocking
p38 MAPK may have a negative impact on anti-inflammatory proteins, as TTP is regulated downstream of p38 MAPK. Thus, we propose (3) to control
the phosphorylation status and activity of TTP. PP2A is an endogenous protein able to activate TTP. Once active, TTP is able to elicit anti-inflammatory
actions by destabilizing cytokine mRNA after recruiting CAF1 and CNOT1.
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altering the airway smooth muscle contractility, causing ob-
struction of airflow (Lakser et al., 2002; Bhavsar et al., 2008);
releasing degradative enzymes, like matrix metalloproteinases
(Woo et al., 2004); and causing the remodeling of airway
architecture by increasing smooth muscle proliferation (Nath
et al., 2006).
p38 MAPK has also been significantly implicated in cortico-
steroid insensitivity (Bhavsar et al., 2008; Chang et al., 2012).
Inhaled corticosteroids are the mainstay of chronic asthma
treatment and are used effectively at low doses for themajority of
asthmatics. However, there is a subset of the asthmatic
population with severe asthma who need maximal doses of
inhaled corticosteroids and another small subset of the asthmatic
population who are resistant to corticosteroids. Details of the
molecular mechanisms thought to be responsible for corticoste-
roid insensitivity and resistance have been outlined in recent
reviews (Ammit, 2013; Barnes, 2013). Interestingly, p38 MAPK
isoforms, p38g (Bhattacharyya et al., 2011) and p38a/b (Mercado
et al., 2012) in particular, may serve as legitimate targets for
restoring corticosteroid responsiveness. Thus, targeting p38
MAPK, perhaps in an isoform-specific manner, might prove to
have clinical efficacy as an anti-inflammatory treatment in
chronic respiratory disease, especially in patients who respond
very poorly to inhaled corticosteroids.
Use of p38 MAPK Inhibitors To Repress
Inflammatory Disease: What Have We Learned?
First-generation inhibitors of p38 MAPK include pharmaco-
logical inhibitors like SB203580, BIRB 796 [1-(3-tert-butyl-1-p-
tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)
urea], SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyr-
idyl)-1H-imidazole], and SB239063 [trans-4-[4-(4-fluorophenyl)-5-
(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol]. These
pyridinyl imidazole compounds competitively antagonize the
ATP-binding site, thereby blocking the activity of p38 MAPK
(Lee et al., 1994). Recent studies of p38 MAPK inhibitors have
used these compounds as a template to create a new set of
slightly remodeled and more selective p38 MAPK inhibitors.
These inhibitors offer a broad range of anti-inflammatory
effects because p38 MAPK is responsible for a large portion of
inflammatory responses. Inhibiting the p38 MAPK pathway in
animal models showed a dramatic reduction in levels of
proinflammatory cytokines and thereby reasonably attenuated
chronic inflammatory responses (Young et al., 1993; Ronkina
et al., 2010). These compounds have not yet been used in the
treatment of asthma, but they have been used marginally in
clinical trials for rheumatoid arthritis (Haddad, 2001) and
Crohn’s disease (Schreiber et al., 2006).
More recently, three molecules have been trialed as potential
anti-inflammatory molecules in COPD. Losmapimod, an oral
inhibitor of p38 MAPK, was shown to be effective in improving
plasma fibrinogen levels and levels of hyperinflation in patients
with COPD (Lomas et al., 2012). However, it was also revealed
to be ineffective in reducing interleukin (IL)-6, IL-8, and
C-reactive protein levels. Similarly, another p38 MAPK inhib-
itor, dilmapimod, was administered as a single oral dose in a
4-week clinical trial and demonstrated reduction in phosphor-
ylated heat shock protein 27 and tumor necrosis factor (TNF)
a production (Singh et al., 2010). Similarly to losmapimod,
dilmapimod was also able to reduce serum fibrinogen and
forced vital capacity but unable to alter levels of IL-6 or
IL-8. Another 6-week clinical study has suggested that
a small-molecule p38MAPK inhibitor, PH-797804 [3-(3-bromo-
4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2H)-yl)-
N,4-dimethylbenzamide] (Xing et al., 2012), was effective in
increasing some measurable airway criteria like forced expi-
ratory volume in 1 second. This study also reported that
PH-797804 reduced systemic fibrinogen and circulating cyto-
kines in patients with moderate to severe COPD in comparison
with patients given placebo. A randomized clinical trial
assessing safety and efficacy of PH-797804 in COPD has been
conducted (MacNee et al., 2013), demonstrating improve-
ments over placebo, albeit with a limited sample size. This
has led to “cautious optimism” (Singh, 2013), although there
is the possibility of unwanted effects and potential for
transient efficacy of p38 MAPK inhibition, as observed with
rheumatoid arthritis.
Efficacy in these trials can be used as a yardstick to
determine if any generation of p38 MAPK inhibitors can be
used as monotherapy or in combination with corticosteroids.
But there are important lessons to be learned from trials of
first-generation p38 MAPK inhibitors in rheumatoid arthri-
tis. The trials have been largely unsuccessful in rheumatoid
arthritis due to the unexpected inefficacy and side effects. The
side effects associated with the use of p38 MAPK inhibitors,
such as hepatotoxicity, dizziness, and skin rash, may occur as
a result of potential nonspecific inhibition (Heinrichsdorff
et al., 2008). The unexpected inefficacy could also be
attributed to the activation of alternate pathways to induce
proinflammatory molecules, including nuclear factor kB (NF-
kB) (Hammaker and Firestein, 2010). Notably, Clark and
Dean (2012) have raised the important issue of p38 MAPK–
driven anti-inflammatory proteins to explain the apparent
failure of p38 MAPK inhibitors in the rheumatology clinic.
They state, “It is likely that the failure of p38 inhibitors is
connected to the important role of the p38 pathway in the
negative feedback control of inflammatory responses” (Clark
and Dean, 2012). That is, inhibiting p38MAPK also blocks the
endogenous anti-inflammatory proteins present that naturally
curtail the inflammatory response. Important anti-inflammatory
molecules, including IL-10, MAPK phosphatase-1, and TTP, are
upregulated in response to increased p38 MAPK activation.
Hence, p38 MAPK inhibitors represent a double-edged sword.
Going farther upstream in the MAPK signaling pathway (see
Fig. 1) could be an alternative option as the therapeutic efficacy
could be higher, but there is a greater risk of incurring further
nonspecific side effects. Another possible option could be to
target the anti-inflammatorymolecules that regulate theMAPK
pathway. Preventing the suppression or prolonging the activa-
tion of the transiently activated anti-inflammatory molecules
could be of therapeutic benefit. This is the promise of TTP.
Alternative Anti-Inflammatory Molecule: TTP
TTP is a critical anti-inflammatory protein that functions to
promote mRNA decay. Many clinically important proteins,
including cytokines, are controlled by post-transcriptional
mRNA-stabilizing mechanisms (Brooks and Blackshear, 2013).
Notably, many of these proteins have been implicated in
asthma (Table 1). We assert that an important consideration
that will likely affect the success of p38 MAPK inhibitors in
respiratory disease is that the expression and function of this
critical anti-inflammatory protein is controlled by p38 MAPK.
TTP as Anti-Inflammatory Therapy 631
Because of this, inhibiting p38 MAPK to repress proinflamma-
tory proteins will also repress important anti-inflammatory
molecules such as TTP.
TTP Is an mRNA-Destabilizing, RNA-Binding
Protein That Enhances mRNA Decay
A role for TTP as a trans-acting anti-inflammatory protein
was first elucidated when the TTP knockout mouse developed
a proinflammatory phenotype due to the overexpression of the
cytokine TNF-a in macrophages, resulting in cachexia, myeloid
hyperplasia, and a host of other inflammatory conditions
(Taylor et al., 1996a). Based on evidence from earlier work
(Caput et al., 1986), it was concluded that TTP confers mRNA
instability and degradation by binding the conserved
adenosine/uridine-rich element (ARE) present within the 39
untranslated region (UTR) of mRNA transcripts containing the
nonameric sequence UUAUUUAUU (Carballo et al., 1998; Lai
et al., 1999). This promotes the poly(A) tail shortening shown in
transcripts of granulocyte-macrophage colony-stimulating fac-
tor and TNF-a (Carballo et al., 2000;Marchese et al., 2010). The
importance of this cis-element is highlighted by its presence in
∼8% of the human transcriptome (Bakheet et al., 2006).
Regulation of inflammatory mediators can occur at the
transcriptional level, controlling gene expression, or it can
occur at the post-transcriptional level, wherebymRNA stability
determines whether a particular transcript is translated to
protein or is rapidly degraded. Regulation can also occur at the
post-translational level by modulating the stability and
longevity of translated proteins. This typically involves either
preventing the degradation of the protein (via the proteasome)
ormodifying it to increase its stability. Although all three levels
of regulatory control can be targeted to modulate an inflamma-
tory response, post-transcriptional modification presents a feasi-
ble opportunity to exert fine control over the proinflammatory
process.
The mRNA transcripts of many inflammatory mediators are
unstable and are regulated post-transcriptionally; this ensures
that low protein levels are maintained under homeostatic
conditions. However, they are rapidly induced and then
degraded depending on the nature of the extracellular cues.
In this way, immunomodulatory cells are able to react with the
appropriate physiologic responses to match the stimuli. In-
flammatory conditions arise when inflammatory proteins are
induced at a time they are not needed or in an amount that is
excessive. Hence, mRNA stability plays a crucial role in the
pathogenesis of inflammatory diseases. This is evident in the
pathogenesis of asthma. Many of the characteristics associated
with asthma, such as basement membrane thickening, in-
creased interstitial matrix deposition, airway smooth muscle
mass increase, increased airway fibrosis, and neovasculariza-
tion in the subepithelial mucosa, can be attributed to elevated
levels of the inflammatory mediators that give rise to these
characteristics (Ammit, 2005). As outlined in Table 1, many of
the TTP target mRNAs encode proteins responsible for these
disease characteristics (Tang and Fiscus, 2001; Mattos et al.,
2002; Hirst, 2003; Batra et al., 2007; Kato and Schleimer, 2007;
Barnes, 2008; Ishmael, 2011; Kang et al., 2011; Rael and
TABLE 1
TTP targets implicated in asthma: potential role of TTP in airway inflammation




Function in Asthma Pathogenesis Cell Lines/Cell Types in which Target IsShown To Be Regulated by TTP
IL-17A Inducing and mediating proinflammatory responses Human T-cell lines (Lee et al., 2012)
IL-6 Proinflammatory (neutrophil production) Various (Neininger et al., 2002; Jalonen et al., 2006; Patil et al., 2008;
Tudor et al., 2009; Van Tubergen et al., 2011; Zhao et al., 2011;
Brahma et al., 2012; Mercado et al., 2012; Chafin et al., 2013;
Banerjee et al., 2014)
IL-1b Many proinflammatory functions Mouse RAW264.7 cells (Chen et al., 2006)
TNF-a Many proinflammatory functions Mouse macrophages (Taylor et al., 1996a; Carballo et al., 1998)
CCL2 Recruitment of inflammatory mediators Mouse macrophages, fibroblasts (Sauer et al., 2006)
CXCL8 Recruitment of neutrophils Various cell lines (Suswam et al., 2008; Balakathiresan et al., 2009;
Bhattacharyya et al., 2011; Al Ghouleh and Magder, 2012;
Galbiati et al., 2012; Mercado et al., 2012; Suswam et al., 2013;
Colin et al., 2014)
GM-CSF Increasing levels of neutrophils and eosinophils Mouse bone marrow–derived stromal cells (Carballo et al., 2000)
VEGF Promoting angiogenesis Various (Essafi-Benkhadir et al., 2007, 2010; Suswam et al., 2008;
Lee et al., 2010; Bhattacharyya et al., 2011; Banerjee et al., 2014)
IL-13 Involved in airway remodeling Mast cells (Barnstein et al., 2006)
IL-23 Neutrophil infiltration Mouse dendritic cells, macrophages (Qian et al., 2011; Molle et al., 2013)
CCL5 Chemotaxis of chemokines and cytokines Mouse dendritic cells, peripheral blood mononuclear cells
(Jin et al., 2012; Rosenberger et al., 2012)
ICAM-1 Recruitment of circulating proinflammatory mediators Human pulmonary microvascular endothelial cells (Mercado et al., 2012;
Colin et al., 2014)
COX-2 Regulation of prostaglandin D2 Various (Phillips et al., 2004; Sully et al., 2004; Tudor et al., 2009;
Hammaker and Firestein, 2010; Bhattacharyya et al., 2011)
iNOS Modulation of airway and vascular smooth muscle tone DLD-1 cells, rat cortical astrocytes (Linker et al., 2005; Lisi et al., 2011)
IL-2 Inducing and mediating proinflammatory responses Mouse splenocytes (Ogilvie et al., 2005)
CXCL1 Neutrophil chemoattractant Mouse macrophages (Datta et al., 2008)
MMP-9 Remodeling of the extracellular matrix Three-dimensional cancer model, chick chorioallantoic membrane
(Van Tubergen et al., 2013)
CCL3 Chemotaxis of chemokines and cytokines,
inflammatory mediator release
Mouse macrophages, fibroblasts (Sauer et al., 2006; Kang et al., 2011)
CCL, C-C ligand; COX, cyclooxygenase; CXCL, C-X-C ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICAM, intercellular adhesion molecule; iNOS,
inducible nitric oxide synthase; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
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Lockey, 2011; Boonpiyathad et al., 2013; Banerjee et al., 2014;
Masaki et al., 2014).
TTP in Respiratory Disease: What Is Known?
The important anti-inflammatory role of TTP has been
extensively studied in mouse models and cell lines, such as
peripheral bloodmonocytes, bonemarrow–derivedmacrophages
(Carballo et al., 2001), HeLa cells and embryonic fibroblasts
(Chen et al., 2012), and a plethora of other cell lines, to elucidate
the molecular mechanisms that drive these anti-inflammatory
functions (Brooks and Blackshear, 2013) (Table 1). To date, the
potential of TTP as an anti-inflammatory therapy has primarily
focused on its role in rheumatoid arthritis, leaving investigations
into the anti-inflammatory function of TTP in airway disease
relatively unexplored. Lessons may also be learned from studies
examining tumors, as many inflammatory tumors have features
that parallel chronic inflammatory diseases like asthma. Among
the similarities are structural remodeling, inflammatory cell
migration, cell proliferation, the induction of proteinases, and
dysregulation of endogenous anti-inflammatory proteins. The
latter characteristic is perhaps themost important similarity, as
there is a prolific induction of inflammatory mediators in both
inflammatory tumors and chronic inflammatory diseases. This
suggests that the endogenous feedback machinery present
within the cell is being dysregulated in cancer. TTP acted as
a tumor suppressor in a model of a specific mast cell tumor by
reducing the pivotal cytokine IL-3 that propagated that tumor
(Stoecklin et al., 2003). Similarly, IL-6, a proinflammatory
mediator shown tomaintain a procancerous inflammatory state,
was reduced by TTP when cells were stimulated with lipopoly-
saccharide (LPS) (Sauer et al., 2006). This, along with studies
that showed that TTP was attenuated in many cancerous cell
lines relative to noncancerous lines (Carrick and Blackshear,
2007; Brennan et al., 2009), presents compelling evidence to
suggest that TTP could be a viable therapeutic target. This is,
however, just a guide, and caution should be exercised when
using tumor models, as they have many limitations. Among the
main limitations, we see that tumors under resistance
mechanisms can induce a host of neoplastic characteristics
not mentioned here. It is not just in cancer models, however,
that TTP has been shown to be effective; TTP was shown to
downregulate cytokines in acute respiratory disease (Colin
et al., 2014), arthritis (Carrick et al., 2004), and psoriasis
(Colin et al., 2014), to highlight a few. It was also shown to be
effective in reducing the immune cell–driven cytokine IL-17A
in the presence of TTP overexpression that was increased when
TTP was silenced (Lee et al., 2012). TTP was also a key anti-
inflammatory protein upregulated in response to antiasthma
drugs in cellular models utilizing human bronchial epithelial
BEAS-2B cells and airway smooth muscle cells (Kaur et al.,
2008).
TTP Function: Multiple Levels of Regulatory
Control
To assess the potential of TTP as an anti-inflammatory
molecule, we have to first gain an understanding of the
mechanisms and molecules that control its regulation. TTP,
also known as Nup475 (DuBois et al., 1990), Tis 11 (Varnum
et al., 1991), G0S24 (Heximer and Forsdyke, 1993), or Zfp36
(Taylor et al., 1991), is the prototypical member of the family
of Cys-Cys-Cys-His class tandem zinc-finger proteins. It is an
immediate early response gene with low levels expressed
within quiescent cells. It can be rapidly expressed and trans-
lated into protein to exert regulatory control upon mRNA
decay. Various studies have shown that TTP is regulated at
different stages of its life cycle. Aswithmany critical molecules,
TTP regulation is possible at the transcriptional level, the post-
transcriptional level, and the post-translational level.
Transcriptional Regulation. At the transcriptional level,
it was shown that the deletion of a single intron from the
promoter region in the Zfp36 59 UTR caused an 85% drop in
serum-induced TTP mRNA (Lai et al., 1995). Structural
analysis of the 59 UTR revealed promoter element binding
sites identified as transcription factor binding sites (Lai et al.,
1995, 1998), including early growth response protein 1, TTP
promoter element 1, activating protein 2–like, and specificity
protein 1. These binding sites in the Zfp36 promoter region
were shown to be partially responsible for TTP transcriptional
activation throughmutational analysis of splice variants in the
presence of serum (DuBois et al., 1990; Lai et al., 1995, 1998;
Kaneda et al., 2000). The same studies also showed that NF-kB
had a binding site on the intron, suggesting that an interaction
could exist between transcription factors to induce TTPmRNA.
A strong interaction was not proven, only that the intron had to
remain in close proximity to the promoter elements. These
data, taken in concert with studies showing the ability of TTP
mRNA to be upregulated by molecules such as TNF-a, LPS,
IL-1b, IL-4, transforming growth factor-b, interferon g, mi-
togenic serum stimuli, cAMP, and phorbol esters, have allowed
us to gain insight into the molecular pathways that drive TTP
mRNA upregulation. Inhibitor studies involving inhibition of
NF-kB, in the presence of IL-1b and LPS, have shown that TTP
mRNA is a direct substrate of the NF-kB signaling pathway
(King et al., 2009; Chen et al., 2013). Other signaling pathways
include the protein kinase C (PKC) pathway, via transcription
factor activating protein 2, which was shown to regulate TTP
mRNA in the presence of a phorbol ester (Chen et al., 1998;
Tan and Parker, 2003; Jalonen et al., 2007; Leppänen et al.,
2008, 2010) and the epidermal growth factor pathway, via
the transcription factor ETS domain–containing protein ELK-1
(Florkowska et al., 2012).
The signalingmoleculemost extensively studied in relation to
TTPmRNA regulation is p38MAPK. The p38MAPK–mediated
pathway exerts most of its control over TTP via the downstream
protein kinase MK2 (Mahtani et al., 2001; Chrestensen et al.,
2004; Stoecklin et al., 2004; Hitti et al., 2006; Tudor et al., 2009;
Marchese et al., 2010); this is discussed in greater detail below.
TTPmRNA is expressed with an immediate early peak followed
by a decline back to near baseline levels after ∼4 hours (Tchen
et al., 2004; Hitti et al., 2006). In the presence of a p38 MAPK
inhibitor, this peak at the early time point was reduced,
suggesting p38 MAPK–dependent regulation of TTP mRNA
expression. It has also been suggested that because TTPmRNA
is increased via the p38 MAPK pathway along with other
pathways, it may be increased in a temporally specific manner,
with NF-kB responsible for the earlymRNA production and p38
MAPK responsible for later time points (Chen et al., 2013).
Taken together, these studies demonstrate that targeting
TTP at the transcriptional level represents an opportunity to
inhibit multiple inhibitory pathways at a downstream level,
because there are a number of signalingmolecules and pathways
that regulate TTP mRNA expression.
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Post-Transcriptional Regulation. It has been widely
reported that the p38 MAPK pathway is responsible for post-
transcriptional regulation of TTP by influencing mRNA stabil-
ity. ActinomycinD chase experiments performed in the presence
of a p38 MAPK inhibitor demonstrated direct reliance on the
p38MAPK for TTPmRNA stability (Carballo et al., 2001; Tchen
et al., 2004). TTP mRNA transcripts were more stable in the
presence of the p38MAPK inhibitor. The ERK pathway has also
been synergistically linked with p38 MAPK to induce TTP
mRNA stability (Brook et al., 2006; Deleault et al., 2008; Essafi-
Benkhadir et al., 2010). Indirectly p38 MAPK is able to
destabilize TTP mRNA through TTP self-regulated mRNA
decay. Examination of TTP 39UTR constructs in the presence of
TTP protein revealed that TTP has a high affinity for its own
mRNA, and as such, it is able to negatively regulate itself
(Brooks et al., 2004; Tchen et al., 2004). This differential
regulation is representative of the complex interaction between
these molecules. Moreover, actinomycin D analysis of TTP
mRNA stability in the presence of a PKC pathway inhibitor
showed that PKChad a similar effect on TTPmRNA stability as
p38 MAPK, thereby suggesting that part of its impact on TTP
may be due to an increase in TTP mRNA stability (Leppänen
et al., 2010).
Another interesting area of focus on the regulation and
function of TTP has been with microRNAs (miRs) and their
ability to impact TTP and bind 39 UTRs of specific mRNA
transcripts. MiRs are small, ∼20 nucleotides in length; they are
regulators of mRNA decay. Accumulating evidence demon-
strates that miRs can regulate TTP; miR-346, for example, was
shown to be important in the regulation of TNF-a in
rheumatoid arthritis, by controlling release of TNF-a directly
via TTP (Semaan et al., 2011), while miR29 was observed to
bind TTPmRNA in a cancermodel (Gebeshuber et al., 2009; Al-
Ahmadi et al., 2013). Another study proposed that TTP does
not directly bind to miR-16 but interacts through association
with Ago/eiF2C family members (proteins required for miR
activity) in a complex with miR16 to assist with the targeting
of AREs (Jing et al., 2005). Moreover, it was reported that
miR-466 bound competitively to IL-10 and conferred anti-
inflammatory properties by antagonizing TTP in Toll-like
receptor–triggered macrophages (Ma et al., 2010). These
reports reveal that miRs have an impact on TTP both directly
or indirectly. So far, whether miRs present within the airways
and implicated in asthma are linked to TTP remains an open
question; however, data from rheumatoid arthritis and cancer
models provide us with an inflammatory model in which miRs
have been shown to alter TTP binding. Further studies
exploring the regulation of TTP by miRs in the context of
asthmatic inflammation are warranted.
Post-Translational Control. Once the stable mRNA tran-
scripts are translated into protein, there is a level of control that
is exercised over the translated protein. Being an immediate
early response gene, TTP protein is rapidly expressed after gene
transcription; hence, TTP protein expression bears a similar
temporal profile to mRNA expression (Mahtani et al., 2001;
Brook et al., 2006). Post-translational regulation of TTP protein
occurs predominantly in the form of phosphorylation. TTP
protein appears in two distinct forms, a phosphorylated form
and an unphosphorylated form. Phosphorylation of TTP is
regulated post-translationally via the ERK and p38 MAPK
pathways (Brook et al., 2006; Deleault et al., 2008; Essafi-
Benkhadir et al., 2010). Other kinase pathways, such as the
PKC pathway, were shown not to have an impact on TTP
protein expression. Post-translational regulation of TTP is also
able to alter its localization to the cytoplasmwith the aid of 14-3-
3 proteins (Johnson et al., 2002; Benjamin et al., 2006; Brook
et al., 2006; Sun et al., 2007). Post-translational control of TTP
function represents a promising means to harness the anti-
inflammatory capacity of TTP, because its phosphorylation
status dictates its activity. Hence, this is explored in greater
depth in the following sections.
TTP Is a Substrate for MK2
TTP’s function as an mRNA-destabilizing factor is mainly
controlled by the p38 MAPK–MK2 axis. Critically, p38 MAPK
also activates the downstream kinase MK2, which phosphor-
ylates murine TTP protein on two key serine residues (Ser52
and Ser178) (Chrestensen et al., 2004). MK2 is a substrate of
the p38 MAPK pathway and has been implicated in post-
translational control of cytokines. This was demonstrated by
using MK2 knockout mice, which had attenuated production of
TNF-a protein when compared with wild-type equivalents.
However, the mRNA levels in wild-type mice were very similar
to those in knockout mice, suggesting that the control exerted
was at the translational level. This also suggested that control
might be imparted via a downstream substrate of MK2. TTP
was shown to be a substrate for MK2 in primary cells by the use
of MK2/TTP double-knockout mice, p38 MAPK inhibitors, and
a reconstituted p38 MAPK transduction pathway using
recombinant kinases to detect TTP phosphorylation (Mahtani
et al., 2001; Hitti et al., 2006; Tudor et al., 2009). Production of
cytokines was also impaired compared withwild type, with IL-6
mRNA half-life, in particular, markedly attenuated (Kotlyarov
et al., 1999; Neininger et al., 2002). In vitro studies revealed
that TTP is phosphorylated by MK2 (Mahtani et al., 2001;
Chrestensen et al., 2004) and phosphorylation of MK2 is able to
modulate TTP function (Stoecklin et al., 2004).
Phosphorylation of TTP Protein
As detailed above, themain function of TTP protein is to decay
target mRNAs; however, its activity is also profoundly affected
by post-translational modification (Cao et al., 2007). Post-
translational phosphorylation appears to be the main factor
responsible for determining its stability, activity, and ability to
form protein complexes. Phosphorylation of TTP has been
extensively studied and mapped, revealing that TTP is a hyper-
phosphorylated protein in vivo, with its mRNA-destabilizing
activity depending on its phosphorylation status. When TTP
protein is phosphorylated, it is unable to affect the stability of
target mRNA; however, when unphosphorylated, it is active and
therefore able to confer its mRNA-destabilizing ability. TTP
protein is more stable when phosphorylated and unstable when
unphosphorylated. This allows TTP protein to be rapidly
degraded by the proteasome when unphosphorylated (Brook
et al., 2006;Hitti et al., 2006). It has also been shown that Ser220
on mouse TTP is phosphorylated via the ERK MAPK pathway
(Taylor et al., 1995), suggesting that dual MAPK involvement
may be required to confer post-translational modifications to
TTP (Brooks et al., 2004). The functions of all the various TTP
phosphorylation sites are not completely understood; however,
the sites for MK2 protein binding have been characterized at
Ser52 and Ser178 on murine TTP (Chrestensen et al., 2004;
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Stoecklin et al., 2004). Phosphorylation at these sites enables
TTP to form complexes with multifunction adaptor 14-3-3
proteins that ablate its function as an mRNA-destabilizing
protein (Chrestensen et al., 2004; Sun et al., 2007; Marchese
et al., 2010). This complex also serves to protect TTP from
dephosphorylation in a protein phosphatase 2A (PP2A)–
dependent manner (Sun et al., 2007) and prevent degradation
of TTP via the proteasome (Deleault et al., 2008; Pfeiffer and
Brooks, 2012). There are, however, some data to suggest that
the role of 14-3-3 proteins might be limited to chaperoning TTP
and only preventing its dephosphorylation (Marchese et al.,
2010; Ngoc et al., 2014). The additional role as a block on
proteasomal degradation is challenged, as recombinant 14-3-3
in the presence of TTP did not affect TTP stability and
degradation by the proteasome (Ngoc et al., 2014). This is in
line with data that showed that TTP levels increased when
cells were in the presence of a proteasome inhibitor. This
complex that forms alters the functionality of TTP without
altering its ability to bind mRNA (Cao et al., 2003; Rigby et al.,
2005; Marchese et al., 2010; Clement et al., 2011), suggesting
that phosphorylated TTP remains inactive while being bound
to target mRNA until it is dephosphorylated. It is then able to
recruit the Ccr4-CAF1 deadenylase components via Not1,
which are then able to rapidly deadenylate the target mRNA,
resulting in their destabilization (Sandler et al., 2011; Colin
et al., 2014). Phosphorylation of TTP also has an impact on its
subcellular localization, with studies showing that upon
stimulation with a mitogen, TTP is rapidly translocated from
the nucleus to the cytoplasm (Taylor et al., 1996b; Johnson
et al., 2002; Brook et al., 2006). This is in line with data
suggesting that degradation of ARE-containing mRNAs occurs
at different locations within the cytoplasm (Franks and Lykke-
Andersen, 2007). Taken together, these studies demonstrate
the importance of the phosphorylation status of TTP in
controlling TTP activity and thus represent a novel area to
target in future pharmacotherapeutic strategies.
Regulation of the Temporal Kinetics of TTP by
p38 MAPK
Knowing the temporal kinetics of TTP may allow us to tailor
pharmacological intervention to increase the anti-inflammatory
efficiency of the process. This would be beneficial as it might
allow us to target specific events within the TTP temporal
regulation rather than the molecule as a whole. The kinetics of
TTP originate with the p38 MAPK pathway or other such
inflammatory pathways.When p38MAPK is phosphorylated, it
becomes active, at which point it then phosphorylates down-
stream targets like MK2. This p38 MAPK upregulation occurs
very soon after the cell is stimulated by some extracellular
trigger. Our own studies in human airway smooth muscle cells
indicate that activation of p38 MAPK occurs as early as 10–15
minutes after stimulation (Quante et al., 2008; Moutzouris
et al., 2010) and possibly even earlier. TTP is a known substrate
for p38 MAPK and MK2, both of which are required for the full
induction of TTP expression. As an immediate early gene, TTP
is rapidly expressed, with our preliminary studies indicating an
increase in mRNA as early as 30 minutes and with one study
showing upregulation as early as 10 minutes (Taylor et al.,
1995). This causes the initial accumulation of TTP mRNA
within the nucleus followed by efficient translation (Taylor
et al., 1996b; Johnson et al., 2002; Brook et al., 2006). During
this period when TTP is inactive, the cytokine mRNA is
stabilized and results in a wave of cytokine upregulation,
peaking at 1 hour (Balakathiresan et al., 2009). This is derived
from the fact that active p38 MAPK has a peak at 15–30
minutes, with activation returning to basal levels after about 1
hour (Quante et al., 2008; Moutzouris et al., 2010). Once p38
MAPK activation has subsided, MK2 is no longer phosphory-
lated and hence is unable to phosphorylate TTP. To determine
the phosphorylation status of TTP using Western blotting can
be challenging; however, earlier studies have used phospha-
tases to identify and confirm the phosphorylated immunoreac-
tive band from the unphosphorylated band (Carballo et al.,
2001; Mahtani et al., 2001; Balakathiresan et al., 2009). Hence,
at the 1-hour time point, the unphosphorylated immunoreac-
tive band of about 40–45 kDa appears, suggesting that TTP is
active (King et al., 2009). The literature suggests that this may
be in part due to the action of PP2A dephosphorylating
phosphorylated TTP, which leads to the rapid deadenylation
and degradation of cytokine mRNAs, thereby potentially
attenuating the degree of inflammation. MAPK phosphatase-1
regulation of p38 MAPK phosphorylation also plays an
important role. Because there appears to be a sequential order
to the control of TTP activity, it can be refined and modified to
aid in the fine-tuning of a potential anti-inflammatory agent.
Regulation of TTP by PP2A
To fully explore TTP and its potential as an anti-inflammatory
agent, it is important to highlight the key molecules that may
positively affect TTP function. We know that TTP is a hyper-
phosphorylated protein, and any protein that could reverse its
inactivation would be of therapeutic value. This is where PP2A
may play a role. PP2A is a heterotrimeric serine-threonine
protein phosphatase consisting of a scaffold subunit, a catalytic
subunit for its phosphatase activity, and a regulatory subunit to
confer substrate specificity (Janssens et al., 2008; Shi, 2009).
PP2A is a master controller of cell signaling and regulates many
cellular functions, including cell growth, inflammation, and
apoptosis (Santoro et al., 1998; Yang et al., 2001). Many of these
functions have been attributed to PP2A-mediated regulation of
MAPKs (Junttila et al., 2008). PP2A is able to act on p38 MAPK
and its upstream kinase MKK3 (Prickett and Brautigan, 2007).
Inhibitors of PP2A, like okadaic acid, calyculin A, and simian
viral protein SV40, were shown to induce phosphorylation and
activate upstream kinases of p38 MAPK and ERK in vitro
(Junttila et al., 2008). It was also shown that inhibition of PP2A
increases stability of cytokine mRNA by increasing the activity
of p38MAPK and its downstream kinase MK2 (Sun et al., 2007;
Clement et al., 2011). These studies are evidence of indirect
regulation of TTP by PP2A. More directly, Brook et al. (2006)
showed that the PP2A inhibitor calyculin A caused accumula-
tion of hyperphosphorylated and stable TTP protein and
highlighted an MK2-Ser52/Ser178-PP2A–dependent mecha-
nism for controlling TTP stability. Because PP2A is able to
regulate p38 MAPK as well as dephosphorylate TTP, TTP is
both an indirect and direct target of PP2A. Thus, PP2A
activation offers promise as a means to control the activity of
TTP, although the fine temporal control needs to be delineated.
Most of the work on PP2A regulation has been performed in
cancer cells (Janssens et al., 2008; Perrotti and Neviani, 2008;
Tay et al., 2012), with some work in mast cells (Kranias et al.,
2010) and respiratory epithelial cells (Cornell et al., 2009).
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Notably, PP2A has emerged as playing an important role in in
vivo models of asthma (Collison et al., 2013; Hatchwell et al.,
2014), and PP2A inhibition (with okadaic acid) resulted in
corticosteroid insensitivity in vitro (Kobayashi et al., 2011).
Strategies targeting PP2A could become therapeutically impor-
tant as an anti-inflammatory approach in asthma.
Summary and Future Directions
The substantial in vitro evidence implicating the p38
MAPK signaling pathway in the pathogenesis of respiratory
diseases driven by inflammation has propelled studies
targeting p38 MAPK as a novel anti-inflammatory strategy
in vivo. However, as discussed in this review, p38 MAPK ac-
tivation also results in repression of critical anti-inflammatory
proteins, in addition to inhibition of proinflammatory mole-
cules. The RNA-destabilizing molecule TTP is one such key
anti-inflammatory protein whose function is significantly re-
pressed by p38 MAPK inhibition. We propose that a greater
understanding of TTP upregulation and its activation by
phosphatases such as PP2A in airway inflammation represents
an alternative anti-inflammatory strategy in chronic respiratory
diseases.
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